Bohac, C., Pal, S., Sweis, R., Kotecha, R., Runcie, K., Bilen, M., … Garmezy, B. (2025). 17A Phase 1, multiple-dose study to evaluate the safety and tolerability of first-in-class XmAb819 (ENPP3 x CD3) in subjects with relapsed or refractory clear cell renal cell carcinoma (ccRCC) (NCT05433). In The Oncologist (Vol. 30). Oxford University Press (OUP). https://doi.org/10.1093/oncolo/oyaf276.018

Bohac, Chet, Sumanta Pal, Randy Sweis, Ritesh Kotecha, Karie Runcie, Mehmet Bilen, David Braun, et al. “17A Phase 1, multiple-dose study to evaluate the safety and tolerability of first-in-class XmAb819 (ENPP3 x CD3) in subjects with relapsed or refractory clear cell renal cell carcinoma (ccRCC) (NCT05433).” In The Oncologist, Vol. 30. Oxford University Press (OUP), 2025. https://doi.org/10.1093/oncolo/oyaf276.018.

Bohac C, Pal S, Sweis R, Kotecha R, Runcie K, Bilen M, et al. 17A Phase 1, multiple-dose study to evaluate the safety and tolerability of first-in-class XmAb819 (ENPP3 x CD3) in subjects with relapsed or refractory clear cell renal cell carcinoma (ccRCC) (NCT05433). In: The Oncologist. Oxford University Press (OUP); 2025.

Bohac, Chet, et al. “17A Phase 1, multiple-dose study to evaluate the safety and tolerability of first-in-class XmAb819 (ENPP3 x CD3) in subjects with relapsed or refractory clear cell renal cell carcinoma (ccRCC) (NCT05433).” The Oncologist, vol. 30, no. Supplement_2, Oxford University Press (OUP), 2025. Crossref, doi:10.1093/oncolo/oyaf276.018.

Bohac C, Pal S, Sweis R, Kotecha R, Runcie K, Bilen M, Braun D, Tykodi S, Hoimes C, Suri V, Kanodia J, Salama E, Woo J, Li L, Yang Y, Franklin R, Maly J, Grigg C, Gulati S, VanderWeele DJ, Garmezy B. 17A Phase 1, multiple-dose study to evaluate the safety and tolerability of first-in-class XmAb819 (ENPP3 x CD3) in subjects with relapsed or refractory clear cell renal cell carcinoma (ccRCC) (NCT05433). The Oncologist. Oxford University Press (OUP); 2025.